2011
The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing
Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, Investigators F, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D, Investigators F, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O, Collaborators F, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M, Investigators F, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G, Investigators and the Consortium of Investigators of Modifiers of BRCA1/2 F, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, LaPolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A, Investigators F, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA, Consortium F. The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research 2011, 17: 3742-3750. PMID: 21385923, PMCID: PMC3107901, DOI: 10.1158/1078-0432.ccr-10-3405.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsCarcinoma, Ovarian EpithelialDisease-Free SurvivalEarly Detection of CancerFemaleGenes, BRCA1Genetic Predisposition to DiseaseGenotypeHumansMicroRNAsNeoplasm InvasivenessNeoplasms, Glandular and EpithelialOvarian NeoplasmsPolymorphism, Single NucleotideProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRiskConceptsOvarian cancerSingle nucleotide polymorphismsOvarian cancer risk evaluationProgression-free survival dataInvasive epithelial ovarian cancerEpithelial ovarian cancerOvarian Cancer Association ConsortiumCause mortality dataModifiers of BRCA1/2Familial ovarian cancerCancer risk evaluationClinical risk predictionConsortium of InvestigatorsOvarian cancer susceptibilityEvidence of associationInvasive EOCSerous EOCFamily historyUnselected casesSurvival timeRisk associationClinical testingKRAS oncogeneClinical testsSerous casesAssociation of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing
Berchuck A, Pharoah P, Ramus S, Gayther S, Palmieri R, Pearce C, Couch F, Antonio A, Goode E, Schildkraut J, Chenevix-Trench G, Sellers T, Risch H, Consortium F. Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing. Gynecologic Oncology 2011, 121: s2-s3. DOI: 10.1016/j.ygyno.2011.02.028.Peer-Reviewed Original Research
2008
Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study
Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, Bradley L, Armel S, Sun P, Narod SA. Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study. Gynecologic Oncology 2008, 112: 68-72. PMID: 19019415, PMCID: PMC3074978, DOI: 10.1016/j.ygyno.2008.10.007.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerClinical genetic testingOvarian cancerGenetic testingGenetic test resultsBlood samplesPositive genetic test resultOntario Cancer RegistryPopulation-based studyEpithelial ovarian cancerProportion of womenCancer RegistryRisk factorsBRCA2 mutationsClinical testingCancerWomenBRCA2BRCA1Small proportionPrevious testingMutationsPatientsTestingRegistry